Knight Therapeutics (KHTRF) Stock Forecast & Price Target

Compare

32 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KHTRF Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Knight

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KHTRF Stock 12 Month Forecast

Average Price Target

$6.06

▲(38.36% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is $6.06 with a high forecast of $7.14 and a low forecast of $5.32. The average price target represents a 38.36% change from the last price of $4.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","3.5":"$3.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.14431,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.32251095,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,3.5,5,6.5,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.389562307692308,4.6191246153846155,4.848686923076923,5.078249230769231,5.3078115384615385,5.537373846153846,5.766936153846154,5.9964984615384616,6.226060769230769,6.455623076923077,6.685185384615385,6.914747692307692,{"y":7.14431,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.306153846153847,4.452307692307692,4.598461538461539,4.7446153846153845,4.890769230769231,5.036923076923077,5.183076923076923,5.329230769230769,5.475384615384615,5.621538461538461,5.7676923076923075,5.913846153846153,{"y":6.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.249423919230769,4.338847838461539,4.428271757692308,4.517695676923077,4.607119596153846,4.696543515384615,4.785967434615385,4.875391353846154,4.964815273076923,5.054239192307692,5.143663111538461,5.233087030769231,{"y":5.32251095,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.3,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.06,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$7.14

Average Price Target$6.06

Lowest Price Target$5.32

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Justin Keywood

Stifel Nicolaus

$5.32

Buy

21.52%

Upside

Reiterated

11/10/25

Stifel Nicolaus Keeps Their Buy Rating on Knight Therapeutics (KHTRF)

David Martin PhD

Bloom Burton

$7.14

Buy

63.11%

Upside

Reiterated

11/07/25

Wall Street Analysts Are Bullish on Top Healthcare PicksWe do expect S&M expense to increase to the $19M level in 4Q-2025 as integration of the Knight and Paladin sales forces during 3Q curtailed spend in this area. At the same time, we expect sales in 3Q- 2025) to benefit from the completed integration in 4Q and going forward. Knight’s oncology/hematology portfolio increased by 1% despite termination of a non- strategic distribution agreement in Colombia. Otherwise, increase was 4% due to growth of Akynzeo, launch of Minjuvi, addition of Orgovyx and Onicit, offset by declines in mature and branded generics products.

Douglas Miehm

RBC Capital

$5.72

Buy

30.49%

Upside

Reiterated

11/07/25

Knight Therapeutics (KHTRF) Receives a Buy from RBC Capital

Bryce Generon

TR | OpenAI - 4o

$4.29

Hold

-2.13%

Downside

Reiterated

11/07/25

AI Generated ArticleAI Generated Article

Unknown Analyst

Raymond James

Not Ranked

Raymond James

$5.72

Buy

30.49%

Upside

Reiterated

08/11/25

Raymond James Sticks to Their Buy Rating for Knight Therapeutics (KHTRF)

Tania Armstrong-Whitworth

Canaccord Genuity

$5→$5.36

Buy

22.33%

Upside

Reiterated

08/07/25

Unknown Analyst

Raymond James

Not Ranked

Raymond James

$4.41→$5.72

Buy

30.49%

Upside

Reiterated

08/06/25

Knight Therapeutics (KHTRF) Receives a Buy from Raymond James

Andre Uddin

Research Capital

$5.36

Buy

22.33%

Upside

Upgraded

03/11/25

Knight Therapeutics upgraded to Buy from Hold at Mackie Research CapitalKnight Therapeutics upgraded to Buy from Hold at Mackie Research Capital

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Justin Keywood

Stifel Nicolaus

$5.32

Buy

21.52%

Upside

Reiterated

11/10/25

Stifel Nicolaus Keeps Their Buy Rating on Knight Therapeutics (KHTRF)

David Martin PhD

Bloom Burton

$7.14

Buy

63.11%

Upside

Reiterated

11/07/25

Douglas Miehm

RBC Capital

$5.72

Buy

30.49%

Upside

Reiterated

11/07/25

Knight Therapeutics (KHTRF) Receives a Buy from RBC Capital

Bryce Generon

TR | OpenAI - 4o

$4.29

Hold

-2.13%

Downside

Reiterated

11/07/25

AI Generated ArticleAI Generated Article

Unknown Analyst

Raymond James

Not Ranked

Raymond James

$5.72

Buy

30.49%

Upside

Reiterated

08/11/25

Raymond James Sticks to Their Buy Rating for Knight Therapeutics (KHTRF)

Tania Armstrong-Whitworth

Canaccord Genuity

$5→$5.36

Buy

22.33%

Upside

Reiterated

08/07/25

Unknown Analyst

Raymond James

Not Ranked

Raymond James

$4.41→$5.72

Buy

30.49%

Upside

Reiterated

08/06/25

Knight Therapeutics (KHTRF) Receives a Buy from Raymond James

Andre Uddin

Research Capital

$5.36

Buy

22.33%

Upside

Upgraded

03/11/25

Knight Therapeutics upgraded to Buy from Hold at Mackie Research CapitalKnight Therapeutics upgraded to Buy from Hold at Mackie Research Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Knight Therapeutics

1 Month

xxx

Success Rate

10/16 ratings generated profit

Average Return

+2.35%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +2.35% per trade.

3 Months

xxx

Success Rate

10/16 ratings generated profit

Average Return

+0.88%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +0.88% per trade.

1 Year

Douglas MiehmRBC Capital

Success Rate

12/24 ratings generated profit

Average Return

-1.05%

reiterated a buy rating 13 days ago

Copying Douglas Miehm's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.05% per trade.

2 Years

xxx

Success Rate

13/24 ratings generated profit

Average Return

+0.07%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 54.17% of your transactions generating a profit, with an average return of +0.07% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KHTRF Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KHTRF has received 9 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. KHTRF average Analyst price target in the past 3 months is 6.06.

Each month's total comprises the sum of three months' worth of ratings.

KHTRF Financial Forecast

KHTRF Earnings Forecast

Next quarter’s earnings estimate for KHTRF is >-$0.01 with a range of -$0.03 to $0.01. The previous quarter’s EPS was -$0.03. KHTRF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year KHTRF has Performed in-line its overall industry.

KHTRF Sales Forecast

Next quarter’s sales forecast for KHTRF is $84.22M with a range of $82.60M to $88.37M. The previous quarter’s sales results were $86.63M. KHTRF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year KHTRF has Performed in-line its overall industry.

KHTRF Stock Forecast FAQ

What is KHTRF’s average 12-month price target, according to analysts?

Based on analyst ratings, Knight Therapeutics’s 12-month average price target is 6.06.

What is KHTRF’s upside potential, based on the analysts’ average price target?

Knight Therapeutics has 38.36% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KHTRF a Buy, Sell or Hold?

Knight Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Knight Therapeutics’s price target?

The average price target for Knight Therapeutics is 6.06. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.14 ,the lowest forecast is $5.32. The average price target represents 38.36% Increase from the current price of $4.38.

What do analysts say about Knight Therapeutics?

Knight Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of KHTRF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Knight Therapeutics (KHTRF) Stock Forecast & Price Target

KHTRF Analyst Ratings

KHTRF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Knight Therapeutics

KHTRF Analyst Recommendation Trends

KHTRF Financial Forecast

KHTRF Earnings Forecast

KHTRF Sales Forecast

KHTRF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts